Drugs / MSC-NP
MSC-NP
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01933802 | Apr 2014 → Dec 2016 | multiple sclerosis | Tisch Multiple Sclerosis Research Center of New York | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT03355365 | Sep 2018 → Feb 2023 | multiple sclerosis | Tisch Multiple Sclerosis Research Center of New York | Completed | Missed primary |
| Phase not stated1 trial | ||||||
| — | NCT03822858 | — | multiple sclerosis | Tisch Multiple Sclerosis Research Center of New York | Available | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MSC-NP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03822858 ↗ |
| Known as | mesenchymal stem cell-derived neural progenitor | “autologous bone marrow mesenchymal stem cell-derived neural progenitor (MSC-NP) treatment in 20 patients with progressive MS” PMID 29449193 ↗ Feb 2018 |
| Known as | Mesenchymal Stem Cell-Derived Neural Progenitor Cells | “Autologous, Bone Marrow-Derived Mesenchymal Stem Cell-Derived Neural Progenitor Cells (MSC-NP), Expanded Ex Vivo; Administered Intrathecally” NCT03822858 ↗ |
| Modality | Cell therapy | “Mesenchymal stem cell-neural progenitors (MSC-NPs) are a bone marrow mesenchymal stem cell (MSC)-derived ex vivo manipulated cell product with therapeutic potential in multiple...” PMID 38783390 ↗ May 2024 |
| Route | Intrathecal | “MSC-NPs were administered intrathecally (IT) in three separate doses of up to 1 × 107 cells per dose” PMID 29449193 ↗ Feb 2018 |